Ignyta cancer news
Ignyta ceased development of preclinical cancer programs RXDX-103, RXDX-107 and RXDX-108 to focus on its molecularly targeted pipeline and reduce operating expenses. The company will focus entrectinib, taladegib, RXDX-105 and RXDX-106. In conjunction with the restructuring, Robert Wild was terminated as CSO and SVP. At Sept. 30, 2015, Ignyta had $139 million in cash and a nine-month operating loss of $49.9 million.
Entrectinib is in the Phase II STARTRK-2 trial to treat solid tumors. The product is an oral inhibitor of c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), neurotrophic tyrosine kinase receptor 1 ( TrkA; NTRK1), TrkB ( NTRK2), TrkC ( NTRK3) and anaplastic lymphoma kinase (ALK). Next half, Ignyta plans to begin Phase II testing of taladegib for cancer. Ignyta has exclusive, worldwide rights to develop and commercialize the small molecule antagonist of smoothened (SMO) and inhibitor of sonic hedgehog homolog (SHH) from Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). ...